For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
India business is growing as per projections; whereas US business will bounce back soon.
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
A pharma industry veteran with over three decades of experience in domestic as well as international markets
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
ICICI Direct gives a preview on the earnings narrative for Q3FY22
Subscribe To Our Newsletter & Stay Updated
